Oxaloacetate Pharmacokinetics and Safety

Completed · Not applicable

Conditions studied: Alzheimer's Disease

In brief

By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.

Key facts

Study ID

NCT02063308

Run by

Russell Swerdlow, MD

People needed

6

Starts

2014-02-01

Expected to finish

2014-06-01

Last updated by the study team

2014-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet criteria for Mild or Moderate AD
• Have a study partner
• Speak English as primary language.

You may not qualify if…

• Absence of a study partner
• Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.